Markets:

Overview

News

Currencies

International

Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

18.47 +0.51 (+2.84%)

Streaming Delayed Price Updated: 1:21 PM EDT, May 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

20 21 Next >

Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2023 ↗

May 16, 2023

Via Benzinga

4 Analysts Have This to Say About NovoCure ↗

May 16, 2023

Via Benzinga

Should You Buy Novocure Stock Right Now? ↗

May 05, 2023

Most Wall Street analysts think this stock will skyrocket. They could be right.

Via The Motley Fool

NovoCure (NVCR) Q1 2023 Earnings Call Transcript ↗

May 04, 2023

NVCR earnings call for the period ending March 31, 2023.

Via The Motley Fool

Novocure Stock Dips As Q1 Earnings Miss Estimates, Higher Costs Hurt Bottom Line ↗

May 04, 2023

Via Benzinga

NovoCure: Q1 Earnings Insights ↗

May 04, 2023

Via Benzinga

What 4 Analyst Ratings Have To Say About NovoCure ↗

March 17, 2023

Via Benzinga

2 Best Defensive Stocks to Buy in March ↗

March 08, 2023

These two defensive stocks should shine in the event of a marketwide correction.

Via The Motley Fool

NovoCure Earnings Perspective: Return On Capital Employed ↗

February 27, 2023

Via Benzinga

Why NovoCure Stock Is Falling Today ↗

February 23, 2023

Investors were looking for a stronger Q4 from the cancer company.

Via The Motley Fool

Novocure Reports First Quarter 2023 Financial Results

May 04, 2023

From Novocure

Via Business Wire

The 3 Most Promising Healthcare Tech Stocks for April 2023 ↗

April 26, 2023

The best healthcare tech stocks provide investors with impressive upside potential, while promising to improve the healthcare sector.

Via InvestorPlace

Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

April 26, 2023

From Novocure

Via Business Wire

Novocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023

April 14, 2023

From Novocure

Via Business Wire

NovoCure (NVCR) Q4 2022 Earnings Call Transcript ↗

February 23, 2023

NVCR earnings call for the period ending December 31, 2022.

Via The Motley Fool

Why Novocure Stock Was so Healthy Today ↗

February 15, 2023

There was good news from the laboratory on Hump Day.

Via The Motley Fool

Novocure to Report First Quarter 2023 Financial Results

April 03, 2023

From Novocure

Via Business Wire

Kristin Stafford Joins Novocure Board of Directors

March 29, 2023

From Novocure

Via Business Wire

Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

March 16, 2023

From Novocure

Via Business Wire

Why Novocure Stock Is Sliding Today ↗

January 19, 2023

Investors reacted negatively to the oncology treatment specialist's game of C-suite musical chairs.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2023 ↗

March 17, 2023

Via Benzinga

2 Stocks That Could Rebound and Rise 30% or More in 2023 ↗

March 10, 2023

They're down, but they aren't yet out.

Via The Motley Fool

Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France

March 01, 2023

From Novocure

Via Business Wire

Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer

March 01, 2023

From Novocure

Via Business Wire

Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

February 23, 2023

From Novocure

Via Business Wire

Allyson J. Ocean, M.D., Joins Novocure Board of Directors

February 23, 2023

From Novocure

Via Business Wire

Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer

February 15, 2023

From Novocure

Via Business Wire

Earnings Scheduled For February 23, 2023 ↗

February 23, 2023

Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.

Via Benzinga

Novocure Round-Trips Its Recent Breakout After Announcing A Series Of C-Suite Changes ↗

January 19, 2023

A series of unexpected C-suite changes sent shares diving again.

Via Investor's Business Daily

Novocure Announces Organizational Changes to Prepare for Future Growth

January 19, 2023

From Novocure

Via Business Wire

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.